Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb will continue to pursue acquisitions, the drug maker's financial chief said, with its war chest bolstered this week by a $1.75 billion cash infusion from a debt refinancing by its Mead Johnson Nutrition Co. (MJN).
By the end of this year, Bristol-Myers expects to have gross cash of more than $10 billion and more than $2 billion in net cash, factoring in the company's debt,

Nov 14 · 4:07:00 PM · Source: The Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto